Bioanalysis Zone

19/09/2025

Gain insight into the key challenges faced in the utilization of cell-based bioanalytical assays to support cell and gene therapies in our upcoming webinar. This webinar will also include the key learnings surrounding Labcorp’s efforts to use SVAR iLite® technology for AAV gene therapies.

Join the discussion >>> https://hubs.ly/Q03GRNFX0

18/09/2025

Targeted mass spectrometry imaging addresses detection challenges with precision and efficiency. Check out our infographic for a quick overview of the benefits.

Download now! >>>

Learn how the combination of two distinct technologies provides a targeted solution for quick, direct and detailed mass spectrometry imaging.

18/09/2025

New interview from Sapient Bioanalytics!

Jeramie Watrous, Co-Founder and Head of Analytical R&D, and Tao Long, Co-Founder and Head of Data Science at Sapient, discuss bridging the gap from large-scale biomarker data to deeper insights that drive discovery, translational research and therapeutic innovation.

"Our goal is to deliver not just data, but meaningful, actionable insights that move their science forward." - Tao

Read the full interview on Bioanalysis Zone >>>

https://hubs.ly/Q03JVD1D0

17/09/2025

Join us on Tuesday, 14 October, as we explore the rapidly evolving area of immunogenicity testing for gene therapy.

Register now to watch it live or when it becomes available on demand! >>> https://hubs.ly/Q03JMJQj0

17/09/2025

Shimadzu's triple quadrupole LC–MS/MS system offers integrated metabolite and elemental profiling for mammalian cell cultures. Download their Application Note to discover how you can revolutionize your cell culture analysis >>> https://bit.ly/4g71WCw

16/09/2025

Learn how the DESI XS system integrates into MSI workflows in our podcast featuring Emmanuelle Claude (Waters) and Andrew Bowman (AbbVie).

Click here! >>>

Dive into the practical applications of mass spectrometry imaging and its transformative impact on the bioanalytical landscape.

11/09/2025

Catch up with Labcorp’s method development expert Amruta Kale in our upcoming webinar.

You’ll get the inside line on their forward-thinking bioassay approaches and their applications in the development of cell and gene therapies.

Register here >>>

Catch up with Labcorp's method development expert Amruta Kale, to get the inside line on their forward-thinking bioassay approaches and their applications in the development of cell and gene therapies.

10/09/2025

In this resource, Shimadzu demonstrate an integrated approach to cell culture medium analysis >>> https://bit.ly/3HQtzmK

09/09/2025

Our latest In the Zone, ‘Targeted mass spectrometry imaging for molecular spatial information’, explores how targeted MSI is addressing detection challenges with higher sensitivity and improved efficiency.

Check out all the features here! >>>

This In the Zone feature will discuss key aspects of MSI and how the Waters Xevo™ TQ Absolute XR, coupled with the DESI™ XS targeted MSI solution, can address challenges in molecular visualization by offering unique, favorable features.

08/09/2025

IQVIA Laboratories company profile – now updated!
New features, publications and lab innovations are now live on the IQVIA Laboratories company profile. Stay current with industry-leading science >>>

IQVIA Laboratories leads with science. For 30+ years, our highly trained bioanalytical scientists have partnered with biotech and pharma companies, providing well-planned strategies to support small and large molecule bioanalysis using LC–MS/MS, HRMS and immunoassay platforms.

05/09/2025

Register for our upcoming webinar in partnership with Labcorp, to learn more about key cell-based assay challenges for bioassays and their solutions.

Save your spot today! >>> https://hubs.ly/Q03GRH8k0

04/09/2025

Special purpose acquisition companies have become an important vehicle for cell and gene therapy companies to go public. In his latest column, Joseph Pategou reviews the high-profile deals that have recently taken place >>>

In his latest column, Joseph reviews how special purpose acquisition companies have impacted the cell and gene therapy field in the last 5 years.